CAMBREX CORP.

History

Year	Detail
1981	Cyril C. Baldwin, Jr. and Arthur Mendolia founded Cambrex Corp. in 1981 as CasChem, a company that manufactures specialty and fine chemicals for niche market segments.
1991	Cambrex entered the life sciences and pharmaceutical industries with the acquisition of Salsbury Chemicals.
1994	Cambrex expanded its operations internationally with the acquisition of Nobel Chemicals AB in Karlskoga, Sweden, and Profarmaco S.r.l. in Milan, Italy.
1995	Cambrex Corp. acquired the Nobel Pharma Chemistry businesses of Nobel Chemicals AB, and Profarmaco S.r.l., located in Karlskoga, Sweden, and Paullo, Milan, Italy, and expanded its portfolio in the pharmaceutical market.
2008	Cambrex Corp. acquired ProSyntest AS, a privately held active pharmaceutical ingredients (API) research and development company, to expand its group of R&D chemists.
2016	Cambrex Corp. expanded its clinical-stage API capabilities with the acquisition of PharmaCore Inc., an early-phase chemistry specialist with expertise in developing, scaling up, and manufacturing small-molecule APIs for clinical-phase projects.
2019	Cambrex Corp. acquired Avista Pharma Solutions, adding early-stage API and finished dosage form development and testing services to its global contract development and manufacturing network.
2022	Cambrex Corp. acquired Q1 Scientific, a provider of environmentally controlled cGMP stability storage services for the pharmaceutical, medical device, and life science industries, located in Waterford, Ireland.
2023	Cambrex Corp. acquired Snapdragon Chemistry, a US-based provider of chemical process development services to a broad range of emerging and established biopharma customers.
2024	Cambrax Corp. collaborated with Eli Lilly and Co. (Lilly) to provide drug substance, drug product, analytical service labs and R&D expertise to Lilly Catalyze360 biotech collaborators.